Moderna Shares Up After Product Sales Outlook

- Advertisement -


By Michael Dabaie
- Advertisement -

Shares of Moderna Inc. were up 6.7% at $228.27 after the company signed advanced purchase agreements for product sales of about $18.5 billion.

- Advertisement -

Moderna says it has signed agreements worth about $18.5 billion for 2022, up from the $17 billion it unveiled in November. The company said it signed off on about $3.5 billion in options, including any potentially updated COVID-19 vaccine booster candidates.

Moderna said it is in active negotiations for additional 2022 COVID-19 vaccine contracts.

- Advertisement -

The company said 807 million doses of its COVID vaccine were shipped globally in 2021, with about 25% going to low- and middle-income countries.

Product sales for 2021 were approximately $17.5 billion.

“While our COVID-19 vaccine is our first drug to market, we have made significant progress in our pipeline of 40 development programs and now have 23 mRNAs in clinical trials,” the company’s chief executive officer, Stefan Bansel, said in a release. programs.”

The company said in a presentation at the JPMorgan Healthcare conference that its product strategy going into 2022 is to bring to market a pan-respiratory annual booster vaccine, which it will continually optimize.

Write to Michael Dabai at [email protected]

,

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox